



Universiteit
Leiden
The Netherlands

Comparison of sleep deprivation and a low dose of ketamine on sleep and the electroencephalogram in Brown Norway rats

Wang, Y.M.; Melgers, M.; Meijer, J.H.; Deboer, T.

Citation

Wang, Y. M., Melgers, M., Meijer, J. H., & Deboer, T. (2023). Comparison of sleep deprivation and a low dose of ketamine on sleep and the electroencephalogram in Brown Norway rats. *Journal Of Sleep Research*, 32(5). doi:10.1111/jsr.13863

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3714818>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH ARTICLE



Comparison of sleep deprivation and a low dose of ketamine on sleep and the electroencephalogram in Brown Norway rats

Yumeng Wang | Marije Melgers | Johanna H. Meijer | Tom Deboer

Department of Cell and Chemical Biology,
Leiden University Medical Center, Leiden, The
Netherlands

Correspondence

Tom Deboer, Laboratory for Neurophysiology,
Department of Cell and Chemical Biology,
Leiden University Medical Center, LUMC
S-05-P, PO Box 9600, 2300, RC Leiden, The
Netherlands.
Email: t.de_boer@lumc.nl

Funding information

China Scholarship Council

Summary

Ketamine is known for its antidepressant effects, but the mechanism underlying this effect remains largely unclear. In contrast to most antidepressant drugs, the action of ketamine is rapid, suggesting a different mode of action. A rapid antidepressant effect is also observed following sleep deprivation (SD). In the present study, we aimed to evaluate the effect of a 6-h SD and acute ketamine treatment on vigilance states, locomotor activity, and electroencephalogram (EEG) power density spectra in Brown Norway rats under constant condition over 2 recording days. After SD and after the initial waking period induced by ketamine, both treatments induced a similar increase in non-rapid eye movement (NREM) sleep and EEG slow-wave activity (SWA) in NREM sleep. Rapid eye movement (REM) sleep was reduced immediately after both treatments but was recovered later only after the SD. The effects on the waking EEG differed between the treatments, with a faster theta peak during and after SD, and no change in the waking spectrum after ketamine. In conclusion, SD and ketamine both lead to an acute increment in NREM sleep SWA as well as in a reduction in REM sleep. The results suggest that selective suppression of REM sleep, combined with enhancement of SWA during NREM may be effective in the treatment of depression.

KEYWORDS

electroencephalogram (EEG), ketamine, power spectrum, sleep, sleep deprivation, slow-wave activity

1 | INTRODUCTION

Sleep quality is thought to be important in learning and memory, cognitive functioning, and mood, and disturbed sleep is a well-known risk factor in mood disorders (Hertenstein et al., 2019; Wong et al., 2013). Sleep abnormalities are commonly associated with psychiatric disorders, e.g., major depressive disorder and bipolar depression disorder, and increasing evidence shows that chronic insufficient sleep may increase the risk of developing depression (Hertenstein et al., 2019; Murphy & Peterson, 2015). Mood disorders like depression are

associated with altered sleep architecture (Murphy & Peterson, 2015). For example, depression is related to a shorter sleep latency, increased rapid-eye movement (REM) sleep duration and REM density, and also decreased non-REM (NREM) sleep (Armitage et al., 2000; Baglioni et al., 2016). NREM sleep and the electroencephalographic (EEG) slow-waves (EEG frequencies <5 Hz) occurring during that sleep are considered to reflect homeostatic sleep pressure (Achermann et al., 1993; Borbely et al., 2016; Ehlers et al., 1996). It has been suggested that impaired homeostatic regulation of slow-wave activity (SWA) is associated with emotional dysregulation

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. *Journal of Sleep Research* published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.

(Goldschmied et al., 2019). Although the mechanism of the bi-directional link between sleep and emotions is complex and not well understood, it still renders sleep a therapeutic target of antidepressant treatment.

Sleep deprivation (SD) and low dosages of the *N*-methyl-D-aspartate receptor (NMDAR) antagonist ketamine are two rapid-acting antidepressant treatment strategies that also influence sleep and the sleep EEG. However, little is known about the effects of ketamine on sleep regulation (Alitalo et al., 2021). Ketamine has a short plasma elimination half-life but can relieve depression symptoms in humans both acutely and on the following days (Berman et al., 2000). Total SD is another rapid acting therapy for depression, which alleviates symptoms of depression in nearly 60% of patients with depression within hours (Hemmeter et al., 2010). Preclinical studies showed that ketamine induced a fast antidepressant effect in rats, 24 or 1 h prior to a forced swim test (Gigliucci et al., 2013). Similar to the effect of ketamine, mice and rats showed decreased immobility in the forced swim test after 12 or 24 h of SD (Hines et al., 2013; Lopez-Rodriguez et al., 2004). Although the positive effect of SD on depression is short-lasting, the rapid antidepressant effect can still be explored and compared with other rapid antidepressants to help us understand the mechanism mediating this action.

To our surprise, the effect of sleep, which showed the most pronounced changes during SD and ketamine treatment, is ignored in 80% of the papers on ketamine, SD, and mood (Alitalo et al., 2021). The aim of this study was to assess to what extent ketamine and SD affect sleep, in both the acute sleep disrupted period and in the long term (2 days), to establish similarities that may be relevant for the antidepressant effect in these two treatments. We observed similar changes in sleep and SWA in NREM sleep immediately after both treatments, and that the main differences between the two treatments lie in their effects on waking behaviour and the EEG power density spectrum during waking in the initial phase of the two treatments. We also observed a long-lasting effect on the EEG power spectrum on the second recovery day in both treatments, and that REM sleep lost in the initial phase was only recovered following SD, but not after ketamine.

2 | METHODS

2.1 | Animals

A total of 20 12-week-old male Brown Norway rats (Charles River) were used in this study. Rats were group-housed under 12:12 h light-dark (LD) condition (lights on 8:00 a.m., lights off 8:00 p.m.) with food and water ad libitum in a temperature-controlled room (21–22°C). During the experiments the rats were in constant darkness, while other conditions (food, water, temperature) remained the same. All animal experiments were approved by the Central Committee on Animals Research (CCD, the Netherlands) and were carried out in accordance with the European Union (EU) Directive 2010/63/EU on the protection of animals used for scientific purposes.

2.2 | Surgical procedure and EEG recordings

At a body weight of ~300 g (16 weeks of age), the rats were put under deep anaesthesia with ketamine (Aescoket, Baxalta, the Netherlands; 65 mg/kg) and Xylazine (Rompun, Bayer AG, Leverkusen, Germany; 13.3 mg/kg) (Y. Wang & Deboer, 2022). The EEG/electromyography (EMG) surgery techniques were used as described previously (Deboer et al., 2003; Y. Wang & Deboer, 2022; Yassenkov & Deboer, 2010). The EEG electrodes (Plastics One) were screwed through the skull on the dura over the right parietal cortex (2.0 mm lateral to the midline, 3.5 mm posterior to bregma) and the cerebellum (at the midline, 1.5 mm posterior to lambda). Two wires with suture patches (Plastics One) were inserted between the skin and the neck muscle tissue for EMG recordings. The wire branches of all electrodes were set in a plastic pedestal (Plastics One, Roanoke, VA, USA), which was fixed to the skull with dental cement and three additional support screws. The rats were single housed after surgery and were allowed to recover for at least 7 days in their home cage under 12:12 h LD condition. After full recovery, the rats were connected to the recording system by a flexible cable and a counterbalanced swivel system, and they remained on the cable under constant darkness in the recording chamber for at least 1 week, which let the rat familiarise with the environment and sleeping with the cable before the start of the recording. The experiments were performed under constant dark conditions because ketamine may influence the circadian clock (Kohtala et al., 2021), and we wanted to ensure that we would not miss this effect if it occurred. The recording chamber was equipped with a passive infrared (PIR) sensor to record locomotor activity and a sensor to record drinking behaviour (Deboer et al., 2003; Y. Wang & Deboer, 2022; Yassenkov & Deboer, 2010). The rats' locomotor activity and drinking activity were recorded continuously to obtain an estimate of the circadian phase (Supplemental Figure S1). From this, onset and offset of rest and activity were determined and an F-periodogram analysis provided an estimate of the circadian period (Stenvers et al., 2016) (Supplementary Figure S1c). This enabled us to determine the time of SD and ketamine treatment for the next recording day and to determine whether SD or ketamine influenced the circadian timing of behaviour.

2.3 | Experimental design

The rats were divided into two groups, one group ($n = 10$) received a 6-h SD, starting at the onset of the rest period, and the other group ($n = 10$) received ketamine and saline within 1 h after the start of the rest phase in a randomised cross-over design experiment. This allowed us to get rid of the confounded results from SD and ketamine/saline treatment in the same rat.

During the 6-h SD, the rats ($n = 10$) were observed with a dim red light in addition to the online EEG recording. Whenever the rats appeared drowsy or the EEG exhibited slow waves, they were mildly disturbed by moderate noise, by the experimenter opening the cages and putting some novel objects inside, and, if necessary, by

introducing fresh food, water, or nesting material into the cage (Deboer et al., 2007; Yassenkov & Deboer, 2010). The rats were never touched during the SD and were not disturbed during feeding and drinking.

Ketamine (Aescoket, Boxtel, The Netherlands) was dissolved in 0.9% saline (LUMC Pharmacy) at a concentration of 25 mg/mL. The concentration was used previously in several studies and is known to induce an antidepressant-like effect accompanied by a moderate increase in activity in both naïve and stressed rats (Gigliucci et al., 2013; Yang et al., 2018). Under constant darkness at circadian time 1 (CT1), 1 h after the predicted offset of locomotor activity, the rats ($n = 10$) received either ketamine (25 mg/kg) or saline at a volume of 1 mL/kg body weight in an intraperitoneal injection under a randomised cross-over design. At least 3 days of rest were given between injections.

2.4 | The EEG data acquisition and EEG power spectrum analysis

The EEG and EMG were simultaneously and continuously recorded for 48 h (after saline and ketamine treatment) and 72 h (before, during, and after SD) as previously described (Deboer et al., 2003; Y. Wang & Deboer, 2022; Yassenkov & Deboer, 2010). The EEG and EMG signals were continuously recorded and amplified (amplification factor ~ 2000) and band-pass filtered (EEG: 0.5–30.0 Hz, -40 dB/decade; EMG 15.0–40.0 Hz, -40 dB/decade), digitised (sampling rate 100 Hz) in 10-s epochs and automatically stored on hard disc (Spike2, Power1401, CED, Cambridge, UK). A fast Fourier transformation routine with a 10-s window was performed offline (MATLAB, The MathWorks Inc., Natick, MA, USA) to compute EEG power density spectra within the frequency range 0.1–25.0 Hz in 0.1 Hz resolution. All data were recorded simultaneously in 10-s epochs. As, for the spectral analysis, it was necessary to re-calculate power density values relative to the first day of the saline control or baseline (first 24-h of the 72-h recording period of the SD experiment) condition, complete and clean recordings from all rats for all days are needed to enter the analysis. Due to problems with the quality of the recordings, two rats from the SD group and one from the ketamine group did not contribute to the SWA and EEG spectral analysis data. The waking, NREM and REM sleep power spectrum were calculated relative to either the baseline (for the SD experiment) or saline (for the ketamine experiment) NREM sleep power spectrum.

2.5 | Data analysis

Three vigilance states (waking, NREM and REM sleep) were scored offline in 10-s epochs. The manual scoring of vigilance states based on the EEG and EMG recordings was performed according to standardised criteria for rats (Deboer et al., 2003; Y. Wang & Deboer, 2022; Yassenkov & Deboer, 2010). Vigilance states were determined, and artefacts were excluded for power spectral analysis. The average

amount of the vigilance states (waking, NREM sleep, REM sleep and REM sleep per total sleep time) were analysed in 1-h intervals and 6-h intervals over 48 and 72 h. The locomotor activity was collected in 10-s intervals and was further averaged in 1- and 6-h intervals. To investigate the effect of SD and ketamine administration on sleep homeostasis, we analysed the EEG power density in the slow-wave range (SWA, 1.0–4.0 Hz) in NREM sleep as described previously (Deboer et al., 2003; Y. Wang & Deboer, 2022). The 1- and 6-h values of SWA in NREM sleep were expressed relative to the first 24 h of the saline or baseline day ($=100\%$). The peak frequency and power density of theta in waking, REM sleep (6.0–9.0 Hz) and slow-waves in NREM sleep (1.0–4.0 Hz) was determined manually in the relative power density spectra in 0.1-Hz bins.

2.6 | Statistics

For data analysis, GraphPad was used. A two-way repeated-measures analysis of variance (ANOVA) was used to compare the effect of SD across time, EEG frequencies, and treatment conditions. Two-way ANOVA was used to compare the effect of drug across time, EEG frequencies, and treatment conditions. Two-way ANOVA was used to compare the effect of drug and SD on EEG peak frequency and power density in this peak. In some cases, where missing values occurred in REM sleep/total sleep and SWA in NREM sleep, a mixed-effects model (restricted maximum likelihood [REML]) was used to compare the effect of SD or ketamine across circadian time. If the result was significant, we ran post hoc Bonferroni multiple comparisons corrected t test, and the significant time points and EEG frequencies are reported in the results. The associated F -statistic is reported in all ANOVA tests. Values of $p < 0.05$ were considered statistically significant.

3 | RESULTS

3.1 | Effect of SD on vigilance states, SWA in NREM sleep, and locomotor activity

The 6-h SD affected sleep and waking over the following 18 h. A clear decrease in waking and increases in NREM and REM sleep were observed (Figure 1a–c, circadian time $\times$ SD interaction, $F_{71, 1278} = 4.942$, $F_{71, 1278} = 4.905$, $F_{71, 1278} = 3.623$ for waking, NREM sleep and REM sleep respectively, $p < 0.0001$). The first 5–6 h after SD a clear decrease in waking and an increase in NREM sleep were seen (Figure 1a, $p_{CT11} = 0.0192$; Figure 1b, $p_{CT8} = 0.035$, $p_{CT11} = 0.0093$) and an increase in REM sleep was observed a few hours later (Figure 1c, $p_{CT14} = 0.0481$). The decrease in waking and increase in NREM sleep were reflected in the first two 6-h values after SD (Figure 1g, time $\times$ SD interaction, $F_{3, 54} = 207.0$, $p < 0.0001$, $p_{CT6-CT12} < 0.0001$, $p_{CT12-CT18} < 0.0001$, Figure 1h, $F_{3, 54} = 206.7$, $p < 0.0001$, $p_{CT6-CT12} < 0.0001$, $p_{CT12-CT18} < 0.0001$). The effects of SD on REM sleep started and ended later than the effects on NREM




FIGURE 1 Legend on next page.

sleep and waking. The 6-h REM sleep values were increased 12–24 h after the end of the SD (Figure 1i, time $\times$ SD interaction, $F_{3, 54} = 109.0$, $p < 0.0001$, $p_{CT12-CT18} < 0.0001$, $p_{CT18-CT24} = 0.0015$). REM/total sleep in the first 6 h after the SD was also lower compared to baseline (Figure 1j, SD, $F_{1, 36} = 61.38$, $p < 0.0001$, $p_{CT6-CT12} < 0.0001$), which was due to the large increase in the amount of NREM sleep. The following active period after the SD (CT12–CT24) showed increased REM/total sleep (Fig. 1 j, SD, $F_{1, 18} = 20.43$, $p = 0.0003$, time $\times$ SD interaction, $F_{3, 54} = 126.5$, $p < 0.0001$, $p_{CT12-CT18} = 0.0004$, $p_{CT18-CT24} = 0.0039$). PIR locomotor activity showed clear modulations across the day (Figure 1e, $F_{71, 1278} = 6.223$, $p < 0.0001$), but there was no difference in locomotor activity found after SD compared to baseline in the post hoc analysis.

The SWA in NREM sleep showed a clear increase immediately after the SD, followed by a declining curve that continued for at least 6 h (Figure 1f, $n =$ eight, circadian time $\times$ SD interaction, $F_{65, 887} = 8.324$, $p < 0.0001$, $p_{CT 7-CT12} < 0.05$). Surprisingly, the rats showed an undershoot in SWA with an average of 79.83% on the second day after SD, compared with baseline condition with an average of 107.6% (Figure 1f, $p_{CT3} = 0.0101$ on recovery day; Supplementary Figure S2, SD, $F_{3, 42} = 18.74$, $p < 0.0001$, $p_{CT0-CT6} < 0.0001$). No effects of SD on the circadian regulation of locomotor activity, or the timing of vigilance states were found.

3.2 | Effect of acute ketamine on vigilance states, SWA in NREM sleep and locomotor activity

Ketamine compared with vehicle, acutely increased waking and reduced NREM and REM sleep for ~ 2 h (Figure 2a, drug, $F_{1, 864} = 8.780$, $p = 0.0031$; circadian time $\times$ drug interaction, $F_{47, 864} = 2.012$, $p < 0.0001$; $p_{CT2} = 0.0046$, $p_{CT3} < 0.0001$; Figure 2b, circadian time $\times$ drug interaction, $F_{47, 864} = 2.220$, $p < 0.0001$, $p_{CT2} = 0.0014$, $p_{CT3} < 0.0001$; Figure 2c, circadian time $\times$ drug interaction, $F_{47, 864} = 1.505$, $p = 0.0172$; $p_{CT3} = 0.0018$; Figure 2d, circadian time $\times$ drug interaction, $F_{47, 844} = 1.580$, $p = 0.0088$). All vigilance state 1-h values subsequently returned to baseline and no differences with vehicle were observed thereafter in any of the vigilance states (Figure 2a–d).

The total amount of NREM sleep over the first 6 h of the day of ketamine treatment did not differ significantly from vehicle (Figure 2h, time $\times$ drug interaction, $F_{3, 72} = 2.710$, $p = 0.0513$), but REM sleep was significantly reduced (Figure 2i, time $\times$ drug interaction, $F_{3, 72} = 4.721$, $p = 0.0046$, $p_{CT0-CT6} = 0.0003$), and waking was

enhanced (Figure 2g, time $\times$ drug interaction, $F_{3, 72} = 4.043$, $p = 0.0103$, $p_{CT0-CT6} = 0.0052$). As can be seen in the hourly values, the acute waking effect of ketamine lasts for 2 h after which sleep is initiated. Although the first 6 h of NREM sleep did not show notable differences between ketamine and saline, NREM sleep was significantly increased ($62.24\% \pm 2.58\%$) compared with saline administration ($46.61\% \pm 2.12\%$) during the second half of that 6 h (CT4–CT6, paired t test, $p = 0.0013$) when the main increase in sleep and SWA was found. Because of the reduction in REM sleep, REM/total sleep was also lower in the first 6-h interval after ketamine compared with vehicle (Figure 2j, drug, $F_{1, 72} = 4.010$, $p = 0.0490$, $p_{CT0-CT6} = 0.0084$). In contrast to NREM sleep, REM sleep did not show big differences ($9.44\% \pm 0.93\%$) compared with saline administration ($11.56\% \pm 0.83\%$) during CT4–CT6 (paired t test, $p = 0.0551$), but due to the increase of NREM sleep, REM/total sleep was decreased significantly ($13.84\% \pm 1.4\%$) compared with saline ($18.66\% \pm 1.3\%$) during CT4–CT6 (paired t test, $p = 0.0145$). REM sleep and REM/total sleep did not show a rebound in the following hours. Locomotor activity was increased for ~ 1 h after ketamine administration compared with vehicle (Figure 2e, circadian time $\times$ drug interaction, $F_{47, 694} = 1.927$, $p = 0.0003$, $p_{CT2} < 0.0001$).

The SWA in NREM sleep after ketamine administration was increased considerably and significantly during CT4 and CT5 (Figure 2f, $n = 9$, drug, $F_{1, 721} = 18.96$, $p < 0.0001$, time $\times$ drug interaction, $F_{46, 721} = 1543$, $p = 0.0135$, $p_{CT4} = 0.0006$, $p_{CT5} < 0.0001$). This was followed by a gradual decline in SWA, similar to the decline seen after SD. However, the undershoot in SWA we observed on the second day after the SD did not occur after ketamine treatment. There was no significant difference on the second day after the ketamine treatment in vigilance states, locomotor activity and SWA compared with vehicle (Figure 2a–f). No effects of ketamine on the circadian regulation of locomotor activity, or the timing of vigilance states were found.

3.3 | Effect of ketamine and SD on the waking EEG power density spectrum

To compare the effect of ketamine and SD on the waking EEG power density spectrum, we analysed the EEG power spectrum of the most active 2 h (CT1–CT3) after ketamine administration, which were mainly spent in waking, and the corresponding 2 h during the SD. The waking power spectrum was examined to determine similarities and differences between waking-induced brain activity during SD and

FIGURE 1 Vigilant stages, locomotor activity and slow-wave activity (SWA) in non-rapid eye movement (NREM) sleep of sleep deprivation (SD) over 72 h. (a–f) Time course of waking, NREM sleep, rapid eye movement (REM) sleep, REM sleep/total sleep time, locomotor activity, and SWA in NREM sleep in 1-h values for sleep deprivation ($n = 10$ rats, $n =$ eight for SWA) in 72 h. The first 24-h was considered as baseline day, the second day was the SD day, the third day was the recovery day. The baseline is repeated in the background in dark grey. The light grey area indicates the SD period. SWA in NREM sleep is expressed relative to the average NREM sleep SWA during the first 24 h ($=100\%$). $*p < 0.05$. (g–i) The 6-h values of waking, NREM sleep, REM sleep, REM sleep/total sleep, locomotor activity, and SWA in NREM sleep for the sleep deprivation (blue, $n = 10$, $n =$ eight rats for SWA analysis) and baseline (grey, $n = 10$, $n =$ eight rats for SWA analysis) condition over 24 h. $**p < 0.01$; $***p < 0.001$; $****p < 0.0001$; CT, circadian time. Data are shown as mean $\pm$ SEM.




FIGURE 2 Legend on next page.

waking-induced brain activity immediately after ketamine treatment. Interestingly, the waking spectrum differed considerably between the two. Power density was increased around 7.7 Hz during the SD but not during waking after the ketamine administration (Figure 3a, $n = 8$, frequency $\times$ SD interaction, $F_{249, 1750} = 1.468$, $p < 0.0001$, $p_{0.3-0.4 \text{ Hz}} < 0.0006$, $p_{7.4-7.9 \text{ Hz}} < 0.05$; Figure 3b, $n = 9$, drug, $F_{1, 3500} = 74.39$, $p < 0.0001$, frequency $\times$ drug interaction, $F_{249, 3500} = 1.253$, $p = 0.0056$). The peak frequencies differed significantly between SD baseline and saline control, which is probably due to the handling of the rats in the saline condition, which did not happen in the SD baseline condition. Concentrating on the theta peak of waking, we found that the peak frequency during SD was faster ($7.5 \pm 0.1 \text{ Hz}$) compared to baseline ($6.1 \pm 0.1 \text{ Hz}$), but that the power density, in the theta peak, when corrected for peak frequency, was not significantly different. Theta peak frequency and amplitude during waking after ketamine administration ($6.9 \pm 0.2 \text{ Hz}$), did not differ from control ($6.7 \pm 0.2 \text{ Hz}$) (Figure 3c, treatment $\times$ group interaction, $F_{1, 30} = 21.82$, $p < 0.0001$, $p_{\text{baseline vs. SD}} < 0.0001$, $p_{\text{baseline vs. saline}} = 0.0273$, $p_{\text{SD vs. ketamine}} = 0.008$; Figure 3d, treatment $\times$ group interaction, $F_{1, 30} = 0.9840$, not significant [ns]).

3.4 | Effect of ketamine and SD on EEG sleep power spectrum during the early recovery period

The 6 h of SD resulted in an increase in sleep and similar results were obtained after the initial 2-h waking period (CT1-CT3) induced by the ketamine administration. To further compare these two treatments, cortical EEG power density spectra were compared between CT6-CT9 of the baseline and SD condition, and CT3-CT6 of vehicle and ketamine administration, which were the times where both treatments gave the highest amount of NREM sleep and the highest SWA in NREM sleep values after treatment. The power spectra in NREM sleep after SD and ketamine both showed the typical increase in EEG SWA (Figure 4a, frequency $\times$ SD interaction, $F_{249, 1750} = 212.9$, $p < 0.0001$, SD, $F_{1, 17,500} = 6763$, $p < 0.0001$, $p_{0.6-4.8 \text{ Hz}} < 0.05$; Figure 4d, frequency $\times$ drug interaction, $F_{249, 4000} = 13.22$, $p < 0.0001$, drug, $F_{1, 4000} = 455.4$, $p < 0.0001$, $p_{0.6-3.2 \text{ Hz}} < 0.05$).

Concentrating on the peak frequency and power density of the SWA peak in NREM sleep, we found that slow-wave power density was increased in the first hours after the SD ($7.60\% \pm 0.31\%$)

compared with baseline ($3.33\% \pm 0.13\%$) (Figure 4j, treatment $\times$ group interaction, $F_{1, 30} = 16.37$, $p = 0.0003$, $p_{\text{baseline vs. SD}} < 0.0001$), but also that the slow-waves were faster compared to baseline (Figure 4g, SD: $1.8 \pm 0.1 \text{ Hz}$, baseline: $1.5 \pm 0.1 \text{ Hz}$, treatment $\times$ group interaction, $F_{1, 30} = 5.678$, $p = 0.0104$, $p_{\text{baseline vs. SD}} = 0.0237$). Compared to the ketamine treatment the slow-wave peak frequency after SD was also faster and had a larger power density (Figure 4g, $p_{\text{SD vs. ketamine}} = 0.0187$; Figure 4j, $p_{\text{SD vs. ketamine}} < 0.0001$). As a control, we compared the spectra between the baseline day of SD and the saline control day and found no significant differences between those two (Figure 4g,j).

In addition, we compared the power density spectra in waking and REM sleep between the two treatments. Notably, after SD, during waking, the rats still displayed higher power density around 7.2 Hz (Figure 4b, SD, $F_{1, 1750} = 50.48$, $p < 0.0001$, $p_{6.6-7.9 \text{ Hz}} < 0.05$). The statistical analysis showed a main effect of drug (Figure 4e, drug, $F_{1, 4000} = 15.51$, $p < 0.0001$) on the waking spectrum after ketamine administration, but the post hoc analysis did not show large differences in individual frequency bins. When comparing theta peak frequency and power density, no significant differences between ketamine and SD were found for theta peak power density during waking after the rats initiated sleep (Figure 4k, treatment $\times$ group interaction, $F_{1,30} = 0.6253$, ns). In the waking power spectrum, after SD, the theta peak frequency was faster compared to baseline (Figure 4h, Baseline: $6.3 \pm 0.1 \text{ Hz}$, SD: $7.1 \pm 0.1 \text{ Hz}$, treatment $\times$ group interaction, $F_{1, 30} = 25.16$, $p < 0.0001$, $p_{\text{baseline vs. SD}} < 0.0001$). Ketamine treatment did not change the waking peak frequency, and the waking theta peak after SD was faster compared to that after ketamine administration (Figure 4h, $p_{\text{SD vs. ketamine}} < 0.0001$).

There was a significant effect of SD on the REM sleep EEG power spectrum (Figure 4c, frequency $\times$ SD interaction, $F_{249,1750} = 2.031$, $p < 0.0001$, $p_{6.1-7.7 \text{ Hz}} < 0.05$), and we also found a main effect of ketamine on the REM sleep power spectrum (Figure 4f, drug, $F_{1, 4000} = 7.660$, $p = 0.0057$), similar to waking. No significant differences between ketamine and SD were found for both theta peak frequency and theta power density in the REM sleep EEG (Figure 4i,l).

3.5 | Effect of ketamine and SD on EEG sleep power spectrum on the second recovery day

As discussed in the introduction, ketamine has an antidepressant effect that lasts longer than the acute effect it has on the vigilance

FIGURE 2 Vigilant stages, locomotor activity and slow-wave activity (SWA) in non-rapid eye movement (NREM) sleep after ketamine and saline treatment. (a-f) Time course of waking, NREM sleep, rapid eye movement (REM) sleep, REM sleep/total sleep time, locomotor activity and SWA in NREM sleep in 1-h values for ketamine and saline administration ($n = 10$ rats, $n = \text{nine}$ for SWA) in 48 h. The first 24-h was considered as treatment or control day, the second day was the recovery day. SWA in NREM sleep is expressed relative to the average NREM sleep SWA during the first 24 h of the saline control day (=100%). * $p < 0.05$. (g-i) The 6-h values of waking, NREM sleep, REM sleep, REM sleep/total sleep, locomotor activity and SWA in NREM sleep for ketamine administration (red, $n = 10$ rats, $n = \text{nine}$ for SWA) and saline (grey, $n = 10$ rats, $n = \text{nine}$ for SWA) administration on the treatment day. The arrow indicates the injection time (CT1). ** $p < 0.01$, *** $p < 0.001$. Data are shown as mean $\pm$ SEM.




FIGURE 3 Acute effect of sleep deprivation (SD) and ketamine administration on the power density spectrum of the waking electroencephalogram (EEG). (a–b) Relative EEG power spectrum in waking during circadian time 1 (CT1)–CT3 for sleep deprivation (blue, $n =$ eight) and baseline (black, $n =$ eight) and after ketamine (red, $n =$ nine) administration or saline (black, $n =$ nine). The red bar indicates significant differences between sleep deprivation and baseline ($p < 0.05$). (c) Peak frequency between 6.0–9.0 Hz in waking during CT1–CT3 for SD (blue, $n =$ eight) and ketamine (red, $n =$ nine) administration. (d) Power density of the peak frequency from (c) in waking during CT1–CT3 for sleep deprivation (blue, $n =$ eight) and ketamine (red, $n =$ nine) administration. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.0001$; ns, not significant. Data are shown as mean $\pm$ SEM.

states and the EEG. Therefore, we analysed the 24 h EEG power density spectra on the second day after the SD and ketamine administration (Figure 5). We only observed main effects on the REM sleep power density spectra after ketamine administration on the second day and no effect on the waking power density spectra (Figure 5f, drug, REM, $F_{1, 4000} = 4.632$, $p = 0.0314$; Figure 5d, drug, waking, $F_{1, 4000} = 1.823$, ns). Similar to ketamine, we found a main effect of SD on the REM sleep power spectrum on the second day (Figure 5c, SD, $F_{1, 1750} = 10.30$, $p = 0.0014$, $p_{6.5 \text{ Hz}} = 0.0189$, $p_{7.4 \text{ Hz}} = 0.0003$, $p_{7.6 \text{ Hz}} = 0.0081$). The effect of SD on the waking power spectrum was small, but still significant (Figure 5b, SD, $F_{1, 1750} = 4.923$, $p = 0.0266$). On the second day after the SD, we observed an undershoot in SWA

(Figure S2), and we anticipated to see a similar effect in the power spectrum. Indeed, we observed between 1.2–2.1 Hz, a decrease in power density the second day after SD, which reflects the undershoot we observed in SWA in Supplementary Figure S2 (Figure 5a, SD, $F_{1, 1750} = 51.94$, $p < 0.0001$, $p_{1.2-2.3 \text{ Hz}} < 0.05$). For the second day of ketamine administration, we noticed a similar effect as after SD in the NREM sleep spectrum, although we did not observe the effect on the hourly values on the second day (Figure 5d, frequency $\times$ drug interaction, $F_{249, 4000} = 1.371$, $p = 0.0002$, $p_{1.2-2.5 \text{ Hz}} < 0.05$). Despite the acute sleep disturbance, ketamine administration and SD were not associated with long-term changes in sleep–wake architecture; however, both SD and ketamine were associated with long-term changes




FIGURE 4 Effect of sleep deprivation (SD) and ketamine administration on the electroencephalogram (EEG) power spectrum during the early recovery phase. (a–c) Relative EEG power spectrum in non-rapid eye movement (NREM) sleep, waking, rapid eye movement (REM) sleep during circadian time 6 (CT6)–CT9 for SD (blue, $n = eight$) and baseline (black, $n = eight$). Red bar indicates significant differences between SD and baseline conditions ($p < 0.05$). (d–f) Relative EEG power spectrum in NREM sleep, waking, REM sleep during CT3–CT6 for saline and ketamine administration (red, $n = nine$) and saline administration (black, $n = nine$). Red bar indicates significant differences between ketamine and saline conditions ($p < 0.05$). (g–i) Peak frequency in the slow-wave range (1–4 Hz) for NREM sleep, and the theta range (6–9 Hz) for waking and REM sleep for SD (blue, $n = eight$) and ketamine (red, $n = nine$) administration. (j–l) EEG power density of the peak frequency in the slow-wave range for NREM sleep, and theta range for waking and REM sleep for SD (blue, $n = eight$) and ketamine (red, $n = nine$) administration. * $p < 0.05$; *** $p < 0.001$, **** $p < 0.0001$; ns, not significant. Data are shown as mean $\pm$ SEM.

in the EEG power density spectra, especially for NREM and REM sleep.

4 | DISCUSSION

4.1 | Effects of SD and ketamine on the sleep–wake architecture and locomotor activity

As found previously, SD induced an increase in NREM sleep and no changes in REM sleep in the first 6 h following the SD (Deboer et al., 2007; Tobler & Borbely, 1990). The increase in NREM sleep lasted for 12 h, and REM sleep started to increase after the increase in NREM sleep started to diminish. It has been shown previously after SD that NREM sleep is more immediately recovered compared to REM sleep; however, not after a relatively short SD of only 6 h. Ketamine, an NMDAR antagonist, initially led to increased waking and activity that has been previously reported in rodents (Ahnaou et al., 2017). This increase lasted approximately 2–3 h, which corresponds well with the reported half-life of 1.3 h of ketamine in the rat (Veilleux-Lemieux et al., 2013). Correspondingly, NMDAR antagonists are known to promote neurotransmitter release that influences brain areas that control arousal (Lorrain et al., 2003), but the induction of waking and suppression of sleep is still not completely understood. In this study, ketamine was expected to induce waking; however, we did not see a change in the amount of NREM sleep during the subsequent sleep period. Acute ketamine reduced REM sleep, which is in line with some of the previous studies, but results tend to vary between studies (Ahnaou et al., 2017). This may be due to differences in light schedules, drug concentration, or species. REM sleep suppression is common with many traditional antidepressants, and in some studies, there exists a relationship between the amount of REM sleep and emotional function (Perogamvros & Schwartz, 2015; Y. Q. Wang et al., 2015). Preclinical studies show that a SD lasting 24-h can increase serotonin (5-hydroxytryptamine [5-HT]) levels in the hippocampus in rats and depletion of 5-HT actually blocks the antidepressant effect of ketamine in rats (Borbely et al., 1980; Gigliucci et al., 2013). This may explain the change of sleep–wake architecture in the context of rapid changes in monoamine levels (Shouse et al., 2000). We observed a reduction in REM sleep for several hours in both treatments. REM sleep eventually recovered after SD, but not after ketamine. In view of the difference in the duration of the antidepressant effect of SD and ketamine, and the difference in the effects on REM sleep between the two treatments, decreased REM sleep and the timing of REM sleep recovery may be relevant for the duration of the antidepressant therapeutic mechanism of the two treatments.

In rodents, ketamine administration can generate a behavioural syndrome characterised by hyperlocomotion, ataxia signs, and stereotypies (Becker et al., 2003). Our recordings were obtained in a restricted condition, and the experimenters could not stay in the recording room and observe the rats after the injection. Increased locomotion, after ketamine was detected from the PIR recording, but did not allow to identify other psychotic-like behaviours. This type of

behaviour was also not observed in another study in rats using the same dosage, after which the rats were observed (Gigliucci et al., 2013). We therefore cannot exclude that this type of behaviour occurred but think that it is unlikely.

4.2 | Acute effect on power spectrum and sleep homeostasis

To investigate this further, we compared the changes in EEG power density spectra during the initial phase of induced waking, the subsequent early recovery phase, and recovery on the second day, and determined similarities and differences that may elucidate the overlaps in their antidepressant action.

We found that the EEG power density spectrum of the waking period, induced in the first 2 h after ketamine treatment, was different from that during SD, which may indicate that the fast antidepressant effect does not result from the type of brain activity during the initial waking period. Remarkably, the increase in locomotor activity after ketamine treatment was not accompanied by a change in theta EEG peak frequency as was the case during SD, where theta peak frequency became faster. Previous studies showed mixed results in rodents, with some studies showing an increase in theta activity in the first 30 min after 30 mg/kg ketamine administration, while other studies showed decreased power density within the range of 2.5–21 Hz (Lazarewicz et al., 2010; Palenicek et al., 2011). The third group of studies found no effect on theta activity (Ahnaou et al., 2017). Recently, a study in humans showed an increase in theta activity after the ketamine administration in healthy subjects (Curic et al., 2021). All these contradicting findings may be due to differences in recording location of the EEG, preceding sleep–wake history, circadian time of day, the drug concentration, and even the species. In the present experiment we found that theta frequency became faster during SD, but when corrected for this change, there was no change in peak power density. The difference in theta frequency between SD and ketamine treatment suggests that the rapid antidepressant effect of ketamine and SD is probably not due to the quality of the initial waking period induced by the treatments.

After SD or the initial wake period induced by ketamine, both treatments showed an increase in the activity in the slow-wave range in the NREM sleep EEG. SWA is thought to reflect the build-up of sleep pressure during waking, which decreases during sleep (Borbely et al., 2016). More and more studies show that increased SWA is associated with increased brain-derived neurotrophic factor, increased synaptic strength, and enhanced synaptic plasticity (Faraguna et al., 2008). We performed our recording for 72-h in constant darkness and noticed that the increase in SWA after SD was similar to that of a 24-h SD in rats under LD condition (Franken et al., 1991). This may indicate that sleep pressure increases faster during waking under constant dark conditions. Further, we noticed an interaction between ketamine and circadian time in SWA over 48 h in our data. It is also possible that the effects of ketamine on sleep homeostasis depend on the circadian time. Considering the similarities in the changes in SWA




FIGURE 5 Effect of sleep deprivation (SD) and ketamine administration on the electroencephalogram (EEG) power spectrum on the second recovery day. (a–c). Relative EEG power spectrum in non-rapid eye movement (NREM) sleep, waking, rapid eye movement (REM) sleep for SD (blue, $n =$ eight) and baseline (black, $n =$ eight). Red bar indicates significant differences between SD and baseline conditions ($p < 0.05$). (d–f) Relative EEG power spectrum in NREM sleep, waking, REM sleep for saline and ketamine administration (red, $n =$ nine) and saline administration (black, $n =$ nine). Red bar indicates significant differences between ketamine and saline conditions. Data are shown as mean $\pm$ SEM.

after SD and ketamine treatment, it may be that SWA in NREM sleep serves as a reflection of an increased neuronal synaptic strength and plasticity and may be related to the mechanism underlying the rapid antidepressant effects of the two treatments (Rantamäki & Kohtala, 2020).

Ketamine did not change the REM sleep EEG power density spectrum. In contrast, we noticed a change in the theta power density during REM sleep after SD. Thus, it seems that similar effects of SD and ketamine on the EEG during the early recovery period are only found in the NREM sleep EEG.

4.3 | Long-term effect on power spectrum and sleep homeostasis

Analysis of the second recovery day after SD and ketamine showed a reduction of SWA in the NREM sleep EEG power spectrum and a

main effect on the REM sleep power spectrum. This may indicate that both SD and ketamine influence sleep homeostasis for a longer time period under constant dark conditions. This is surprising, as the plasma elimination half-life of ketamine (1.3–1.5 h in rats) is short (Veilleux-Lemieux et al., 2013), and nevertheless, the changes we observed remained for at least 24 h after administration. As we observed an undershoot in SWA on the second day, which is not seen in other rat studies with such a short (6 h) SD (Deboer et al., 2007). Undershoots in SWA, or negative rebounds as they are also called, have been observed before after SD in rats, but then after a 24-h SD (Franken et al., 1991). The strong undershoot we observed may be related to the delayed compensation in REM sleep, which may suppress SWA in those hours. In summary, it seems that the effects of SD on NREM sleep SWA and REM sleep in our experiment are relatively strong when compared to other studies with a 6-h SD in rats. In contrast to the strong acute sleep disturbance, ketamine administration and SD were not associated with long-term changes in

sleep–wake architecture; however, both SD and ketamine were associated with long-term changes in the EEG power density spectrum, especially in the NREM and REM sleep EEG.

There is a strong link between sleep and major depression. However, the causal relationship remains unclear. It is, for instance, unknown whether changes in depression symptoms precede or follow changes in sleep, and whether a longer or shorter sleep duration is related to improvements of depression core symptoms (Borbely et al., 2016; Lorenz et al., 2020). Investigating this may further explain how and when an acute SD exerts its rapid antidepressant effect and why it typically relapses after subsequent sleep occurs. It also needs to be researched how, with for instance light therapy, the antidepressant effect can be extended (Benedetti et al., 2014; Giedke & Schwarzler, 2002; Wirz-Justice & Terman, 2012; Wu et al., 2009). Other questions that remain are whether it suffices to concentrate on NREM sleep or total SD (Borbely et al., 2016), as in the past successful treatments were also achieved with REM SD (Vogel, 1983).

One of the limitations of this study are that we did not sample the EEG frequency over 25 Hz. It has been shown in other studies that, low dosages of ketamine increase EEG power density of gamma frequencies (30–100 Hz) in both human and rodents (Castro-Zaballa et al., 2018; Georgiou et al., 2022; Hong et al., 2010). This enhanced gamma activity was associated with higher arousal or alertness (Makeig & Jung, 1996). A second limitation is that we did not use an animal model that shows behaviours characteristic of depression, but only report on healthy rats. Future studies should also include the analysis of the coherence of other cortex regions and EEG bands that have been shown to be involved in responding to ketamine or SD, such as gamma oscillations and should include animal models of depression when possible.

Taken together, the common actions of SD and ketamine on sleep consist of an acute increase in NREM sleep SWA and a reduction in REM sleep. This suggests that these two effects may be related to the rapid antidepressant effect seen after both. The finding that REM sleep eventually recovers after SD, but not after ketamine is in accordance with the assumption that reducing the amount of REM sleep and increasing REM sleep latency is antidepressant in both of these treatments, and fits with previous findings showing that the effect of SD on depressive symptoms is transient and after ketamine longer lasting (Berman et al., 2000; Wirz-Justice & Van den Hoofdakker, 1999). The latter suggests that reducing REM sleep may be an important feature of a sustainable positive effect on depressive symptoms after ketamine treatment. The acute application of SD and ketamine appear to induce similar cortical changes during NREM and REM sleep and may further influence long-lasting effects in the brain. Therefore, our data suggest that a previously unappreciated targeting of NREM sleep SWA, and REM sleep may help to improve antidepressant therapies.

AUTHOR CONTRIBUTIONS

Y. Wang and T. Deboer designed the study. Y. Wang collected the data. Y. Wang, M. Melgers and T. Deboer analysed the data, Y. Wang, J. H. Meijer, and T. Deboer wrote the manuscript.

ACKNOWLEDGMENTS

Y. Wang gladly acknowledges the scholarship from the China Scholarship Council for supporting this work.

CONFLICT OF INTEREST STATEMENT

All authors declare not having any conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Tom Deboer  <https://orcid.org/0000-0002-6402-6248>

REFERENCES

- Achermann, P., Dijk, D. J., Brunner, D. P., & Borbely, A. A. (1993). A model of human sleep homeostasis based on EEG slow-wave activity: Quantitative comparison of data and simulations. *Brain Research Bulletin*, 31(1–2), 97–113. [https://doi.org/10.1016/0361-9230\(93\)90016-5](https://doi.org/10.1016/0361-9230(93)90016-5)
- Ahnaou, A., Huysmans, H., Biermans, R., Manyakov, N. V., & Drinkenburg, W. (2017). Ketamine: Differential neurophysiological dynamics in functional networks in the rat brain. *Translational Psychiatry*, 7(9), e1237. <https://doi.org/10.1038/tp.2017.198>
- Alitalo, O., Saarreharju, R., Henter, I. D., Zarate, C. A., Jr., Kohtala, S., & Rantamaki, T. (2021). A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants. *Progress in Neurobiology*, 206, 102140. <https://doi.org/10.1016/j.pneurobio.2021.102140>
- Armitage, R., Hoffmann, R., Trivedi, M., & Rush, A. J. (2000). Slow-wave activity in NREM sleep: Sex and age effects in depressed outpatients and healthy controls. *Psychiatry Research*, 95(3), 201–213. [https://doi.org/10.1016/s0165-1781\(00\)00178-5](https://doi.org/10.1016/s0165-1781(00)00178-5)
- Baglioni, C., Nanovska, S., Regen, W., Spiegelhalter, K., Feige, B., Nissen, C., Reynolds, C. F., & Riemann, D. (2016). Sleep and mental disorders: A meta-analysis of polysomnographic research. *Psychological Bulletin*, 142(9), 969–990. <https://doi.org/10.1037/bul0000053>
- Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., & Grecksch, G. (2003). Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 27(4), 687–700. [https://doi.org/10.1016/S0278-5846\(03\)00080-0](https://doi.org/10.1016/S0278-5846(03)00080-0)
- Benedetti, F., Riccaboni, R., Locatelli, C., Poletti, S., Dallaspezia, S., & Colombo, C. (2014). Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression. *The Journal of Clinical Psychiatry*, 75(2), 133–140. <https://doi.org/10.4088/JCP.13m08455>
- Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. *Biological Psychiatry*, 47(4), 351–354. [https://doi.org/10.1016/s0006-3223\(99\)00230-9](https://doi.org/10.1016/s0006-3223(99)00230-9)
- Borbely, A. A., Daan, S., Wirz-Justice, A., & Deboer, T. (2016). The two-process model of sleep regulation: A reappraisal. *Journal of Sleep Research*, 25(2), 131–143. <https://doi.org/10.1111/jsr.12371>
- Borbely, A. A., Steigrid, P., & Tobler, I. (1980). Effect of sleep deprivation on brain serotonin in the rat. *Behavioural Brain Research*, 1(2), 205–210. [https://doi.org/10.1016/s0166-4328\(80\)80058-1](https://doi.org/10.1016/s0166-4328(80)80058-1)
- Castro-Zaballa, S., Cavelli, M. L., Gonzalez, J., Nardi, A. E., Machado, S., Scorza, C., & Tortorolo, P. (2018). EEG 40 Hz coherence decreases in REM sleep and ketamine model of psychosis. *Frontiers in Psychiatry*, 9, 766. <https://doi.org/10.3389/fpsy.2018.00766>

- Curic, S., Andreou, C., Nolte, G., Steinmann, S., Thiebes, S., Polomac, N., Haaf, M., Rauh, J., Leicht, G., & Mulert, C. (2021). Ketamine alters functional gamma and theta resting-state connectivity in healthy humans: Implications for schizophrenia treatment targeting the glutamate system. *Frontiers in Psychiatry*, 12, 671007. <https://doi.org/10.3389/fpsy.2021.671007>
- Deboer, T., Detari, L., & Meijer, J. H. (2007). Long term effects of sleep deprivation on the mammalian circadian pacemaker. *Sleep*, 30(3), 257–262. <https://doi.org/10.1093/sleep/30.3.257>
- Deboer, T., Vansteensel, M. J., Detari, L., & Meijer, J. H. (2003). Sleep states alter activity of suprachiasmatic nucleus neurons. *Nature Neuroscience*, 6(10), 1086–1090. <https://doi.org/10.1038/nn1122>
- Ehlers, C. L., Havstad, J. W., & Kupfer, D. J. (1996). Estimation of the time course of slow-wave sleep over the night in depressed patients: Effects of clomipramine and clinical response. *Biological Psychiatry*, 39(3), 171–181. [https://doi.org/10.1016/0006-3223\(95\)00139-5](https://doi.org/10.1016/0006-3223(95)00139-5)
- Faraguna, U., Vyazovskiy, V. V., Nelson, A. B., Tononi, G., & Cirelli, C. (2008). A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. *The Journal of Neuroscience*, 28(15), 4088–4095. <https://doi.org/10.1523/JNEUROSCI.5510-07.2008>
- Franken, P., Dijk, D. J., Tobler, I., & Borbely, A. A. (1991). Sleep deprivation in rats: Effects on EEG power spectra, vigilance states, and cortical temperature. *The American Journal of Physiology*, 261(1 Pt 2), R198–R208. <https://doi.org/10.1152/ajpregu.1991.261.1.R198>
- Georgiou, P., Zanos, P., Mou, T. M., An, X., Gerhard, D. M., Dryanovski, D. I., Potter, L. E., Highland, J. N., Jenne, C. E., Stewart, B. W., Pultorak, K. J., Yuan, P., Powels, C. F., Lovett, J., Pereira, E. F. R., Clark, S. M., Tonelli, L. H., Moaddel, R., Zarate, C. A., Jr., ... Gould, T. D. (2022). Experimenters' sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor. *Nature Neuroscience*, 25(9), 1191–1200. <https://doi.org/10.1038/s41593-022-01146-x>
- Giedke, H., & Schwarzler, F. (2002). Therapeutic use of sleep deprivation in depression. *Sleep Medicine Reviews*, 6(5), 361–377 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12531127>
- Gigliucci, V., O'Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013). Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. *Psychopharmacology*, 228(1), 157–166. <https://doi.org/10.1007/s00213-013-3024-x>
- Goldschmied, J. R., Cheng, P., Hoffmann, R., Boland, E. M., Deldin, P. J., & Armitage, R. (2019). Effects of slow-wave activity on mood disturbance in major depressive disorder. *Psychological Medicine*, 49(4), 639–645. <https://doi.org/10.1017/S0033291718001332>
- Hemmeter, U. M., Hemmeter-Spernal, J., & Krieg, J. C. (2010). Sleep deprivation in depression. *Expert Review of Neurotherapeutics*, 10(7), 1101–1115. <https://doi.org/10.1586/ern.10.83>
- Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalter, K., Johann, A., Jansson-Fröjmark, M., Palagini, L., Rücker, G., Riemann, D., & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. *Sleep Medicine Reviews*, 43, 96–105. <https://doi.org/10.1016/j.smrv.2018.10.006>
- Hines, D. J., Schmitt, L. I., Hines, R. M., Moss, S. J., & Haydon, P. G. (2013). Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling. *Translational Psychiatry*, 3, e212. <https://doi.org/10.1038/tp.2012.136>
- Hong, L. E., Summerfelt, A., Buchanan, R. W., O'Donnell, P., Thaker, G. K., Weiler, M. A., & Lahti, A. C. (2010). Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. *Neuropsychopharmacology*, 35(3), 632–640. <https://doi.org/10.1038/npp.2009.168>
- Kohtala, S., Alitalo, O., Rosenholm, M., Rozov, S., & Rantamaki, T. (2021). Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine. *Pharmacology & Therapeutics*, 221, 107741. <https://doi.org/10.1016/j.pharmthera.2020.107741>
- Lazarewicz, M. T., Ehrlichman, R. S., Maxwell, C. R., Gandal, M. J., Finkel, L. H., & Siegel, S. J. (2010). Ketamine modulates theta and gamma oscillations. *Journal of Cognitive Neuroscience*, 22(7), 1452–1464. <https://doi.org/10.1162/jocn.2009.21305>
- Lopez-Rodriguez, F., Kim, J., & Poland, R. E. (2004). Total sleep deprivation decreases immobility in the forced-swim test. *Neuropsychopharmacology*, 29(6), 1105–1111. <https://doi.org/10.1038/sj.npp.1300406>
- Lorenz, N., Sander, C., Ivanova, G., & Hegerl, U. (2020). Temporal associations of daily changes in sleep and depression Core symptoms in patients suffering from major depressive disorder: Idiographic time-series analysis. *JMIR Mental Health*, 7(4), e17071. <https://doi.org/10.2196/17071>
- Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. *Neuroscience*, 117(3), 697–706. [https://doi.org/10.1016/s0306-4522\(02\)00652-8](https://doi.org/10.1016/s0306-4522(02)00652-8)
- Makeig, S., & Jung, T. P. (1996). Tonic, phasic, and transient EEG correlates of auditory awareness in drowsiness. *Brain Research. Cognitive Brain Research*, 4(1), 15–25. [https://doi.org/10.1016/0926-6410\(95\)00042-9](https://doi.org/10.1016/0926-6410(95)00042-9)
- Murphy, M. J., & Peterson, M. J. (2015). Sleep disturbances in depression. *Sleep Medicine Clinics*, 10(1), 17–23. <https://doi.org/10.1016/j.jsmc.2014.11.009>
- Palenicek, T., Fujakova, M., Brunovsky, M., Balikova, M., Horacek, J., Gorman, I., Tylš, F., Tišlerová, B., Soš, P., Bubeniková-Valešová, V., Höschl, C., & Krajca, V. (2011). Electroencephalographic spectral and coherence analysis of ketamine in rats: Correlation with behavioral effects and pharmacokinetics. *Neuropsychobiology*, 63(4), 202–218. <https://doi.org/10.1159/000321803>
- Perogamvros, L., & Schwartz, S. (2015). Sleep and emotional functions. *Current Topics in Behavioral Neurosciences*, 25, 411–431. https://doi.org/10.1007/7854_2013_271
- Rantamaki, T., & Kohtala, S. (2020). Encoding, consolidation, and renormalization in depression: Synaptic homeostasis, plasticity, and sleep integrate rapid antidepressant effects. *Pharmacological Reviews*, 72(2), 439–465. <https://doi.org/10.1124/pr.119.018697>
- Shouse, M. N., Staba, R. J., Saquib, S. F., & Farber, P. R. (2000). Monoamines and sleep: Microdialysis findings in pons and amygdala. *Brain Research*, 860(1–2), 181–189. [https://doi.org/10.1016/s0006-8993\(00\)02013-8](https://doi.org/10.1016/s0006-8993(00)02013-8)
- Stenvers, D. J., van Dorp, R., Foppen, E., Mendoza, J., Opperhuizen, A. L., Fliers, E., Bisschop, P. H., Meijer, J. H., Kalsbeek, A., & Deboer, T. (2016). Dim light at night disturbs the daily sleep-wake cycle in the rat. *Scientific Reports*, 6, 35662. <https://doi.org/10.1038/srep35662>
- Tobler, I., & Borbely, A. A. (1990). The effect of 3-h and 6-h sleep deprivation on sleep and EEG spectra of the rat. *Behavioural Brain Research*, 36(1–2), 73–78. [https://doi.org/10.1016/0166-4328\(90\)90161-7](https://doi.org/10.1016/0166-4328(90)90161-7)
- Veilleux-Lemieux, D., Castel, A., Carrier, D., Beaudry, F., & Vachon, P. (2013). Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. *Journal of the American Association for Laboratory Animal Science*, 52(5), 567–570 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/24041212>
- Vogel, G. W. (1983). Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 7(2–3), 343–349. [https://doi.org/10.1016/0278-5846\(83\)90122-7](https://doi.org/10.1016/0278-5846(83)90122-7)
- Wang, Y., & Deboer, T. (2022). Long-term effect of a single dose of caffeine on sleep, the sleep EEG and neuronal activity in the Peduncular part of the lateral hypothalamus under constant dark conditions. *Clocks & Sleep*, 4(2), 260–276. <https://doi.org/10.3390/clockssleep4020023>
- Wang, Y. Q., Li, R., Zhang, M. Q., Zhang, Z., Qu, W. M., & Huang, Z. L. (2015). The neurobiological mechanisms and treatments of REM sleep disturbances in depression. *Current Neuropharmacology*, 13(4), 543–553. <https://doi.org/10.2174/1570159x13666150310002540>

- Wirz-Justice, A., & Terman, M. (2012). Chronotherapeutics (light and wake therapy) as a class of interventions for affective disorders. *Handbook of Clinical Neurology*, 106, 697–713. <https://doi.org/10.1016/B978-0-444-52002-9.00042-5>
- Wirz-Justice, A., & Van den Hoofdakker, R. H. (1999). Sleep deprivation in depression: What do we know, where do we go? *Biological Psychiatry*, 46(4), 445–453. [https://doi.org/10.1016/S0006-3223\(99\)00125-0](https://doi.org/10.1016/S0006-3223(99)00125-0)
- Wong, M. L., Lau, E. Y., Wan, J. H., Cheung, S. F., Hui, C. H., & Mok, D. S. (2013). The interplay between sleep and mood in predicting academic functioning, physical health and psychological health: A longitudinal study. *Journal of Psychosomatic Research*, 74(4), 271–277. <https://doi.org/10.1016/j.jpsychores.2012.08.014>
- Wu, J. C., Kelsoe, J. R., Schachar, C., Bunney, B. G., DeModena, A., Golshan, S., Gillin, J. C., Potkin, S. G., & Bunney, W. E. (2009). Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. *Biological Psychiatry*, 66(3), 298–301. <https://doi.org/10.1016/j.biopsych.2009.02.018>
- Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018). Ketamine blocks bursting in the lateral habenula to rapidly relieve

depression. *Nature*, 554(7692), 317–322. <https://doi.org/10.1038/nature25509>

Yasenkova, R., & Deboer, T. (2010). Circadian regulation of sleep and the sleep EEG under constant sleep pressure in the rat. *Sleep*, 33(5), 631–641. <https://doi.org/10.1093/sleep/33.5.631>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Wang, Y., Melgers, M., Meijer, J. H., & Deboer, T. (2023). Comparison of sleep deprivation and a low dose of ketamine on sleep and the electroencephalogram in Brown Norway rats. *Journal of Sleep Research*, 32(5), e13863. <https://doi.org/10.1111/jsr.13863>